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Conclusions: We conclude that transfusion of blood products is
an integral part of stem cell transplantation. Role of growth factors
and lowering the threshold of transfusion in an attempt to decrease
the need of transfusion should be studied in a prospective fashion.
Decreased survival in patients receiving more transfusion could be
due to the nature and severity of underlying disease rather than an
independent risk factor for survival.
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International guidelines recommend revaccination of haemopoietic
stem cell transplant (HSCT) recipients. We surveyed practice in
HSCT centres in the UK & Ireland. The response rate was 29/52
(56%): 9 did autologous (AUTO) transplants only & 20 performed
allografts/autografts in adults &/or children (AUTO/ALLO). Re-
sponders represented 58% of recorded transplants (2003-2005).
Vaccination post-autologous HSCT was intended by 4/9 AUTO
centres and 12/20 AUTO/ALLO centres. Vaccinations post-au-
tograft were given by centres as follows: Combined/selective Diph-
theria, Tetanus & Pertussis (DTP) (38%), Haemophilus B (HiB)
(45%) , Meningococcus C (MC) (34%), Poliomyelitis (Polio) (31%,
Salk), Hepatitis A (HA) (3%), Inﬂuenza A (Flu A) (45%) and Strep-
tococcus pneumoniae (SP) (45%). Selected patients were routinely
vaccinated against Measles / Mumps / Rubella (MMR) (28% centres)
and Hepatitis B (HB) (10%). Antibody titres or CD4 cell counts
guided timing of post-autologous HSCT vaccination in 4 & 1 centre
respectively.
Vaccinations post-allograft were planned by centres as follows:
DTP (100%), HiB (90%), MC (80%), Polio (95%, Salk), Flu A
(100%) and SP (95%). Selected patients were routinely vaccinated
against HB (25%) and HA (10%). CD4 cell counts guided timing of
post-allograft vaccination in 2 centres.
Live vaccines were avoided by 4 ALLO/AUTO centres: MMR was
given at 18-30 months post allograft in the rest provided there was no
active Graft versus Host Disease or ongoing Immunosuppressive
medication (I/S) . Bacillus Calmette Guerin was considered by 1
centre for high risk patients without GVHD or I/S.
Household contacts were advised to consider vaccination against Flu
A in 17% centres while Salk polio vaccine was advised by 10% centres.
Penicillin V prophylaxis against SP was recommended by 6
centres post Autograft for 6-12 months or life if Total Body
Irradiation had been given. Lifelong penicillin was advocated for
all allografted patients by 9 centres and in selected patients by 3
centres. Episodes of severe Pneumococccal sepsis was reported by
24% centres independent of prior vaccination or penicillin.
Reasons for large variation, particularly among autologous HSCT
recipients, may include lack of Grade A evidence, perceived poor
efﬁcacy and patient non-compliance. Systematic multicentre prospec-
tive evaluation of immune-reconstitution and incidence of speciﬁc
infections may clarify the value of post SCT vaccination in prevention
of life threatening infection.
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Background: In about 20% of allogeneic stem cell transplantation
(SCT) minor ABO incompatibility does exist. This is accompanied
with the risk of severe hemolysis especially during hematopoietic
regeneration. The risk of hemolysis increases if peripheral blood stem
cells are used instead of bone marrow (BM) and a graft-versus-host
disease (GvHD) prophylaxis without methotrexate (MTX). As we
have observed lethal hemolyses in patients undergoing minor ABO
mismatched SCT following reduced intensity conditioning (RIC) we
decided to perform prophylactic red blood cell exchange (RBCX) in
all consecutive patients undergoing RIC prior to SCT with a minor
ABO incompatible donor.
Materials and Methods: From April 1999 to March 2006, 112
consecutive patients underwent SCT with a sibling (n55) or unre-
lated donor graft (n57) after RIC. GvHD prophylaxis consisted of
CyA and mycophenolate mofetil (MMF). Fifty-four patients had an
ABO-identical donor, 33 received an ABO-minor/bidirectional and
25 an ABO-major incompatible graft, respectively. RBCX was per-
formed between day -5 and -1, removing 1 time patients RBCmass to
reduce his remaining RBCs to about 40%. Packed RBCS of group 0
were used as exchange ﬂuid.
Results: So far, 20 patients underwent prophylactic RBCX before
SCT. The procedure was tolerated well in 16 (80%) patients, 2
developed citrate toxicity and 2 nausea and hypotension during treat-
ment leading to discontinuation of RBCX in the latter patients.
Whereas 18 patients did not experience any signs of hemolysis after
minor ABO incompatible SCT, 2 showed a marked increase in lactic
dehydrogenase and serum bilirubin levels without a drop of hemato-
crit levels below 28% during hematologic recovery. Six of 20 patients
with prophylactic RBCX died between 4.3 and 29.2 months after
SCT of GvHD and infection (n3), invasive aspergillosis (n1) and
relapse of hematologic disease (n2). One patient rejected his graft
within 1 month. The other 13 (64%) patients are in continuous
complete remission a median of 13.9 months (1.2 to 36) after SCT.
Conclusion: RBCX is a save and well tolerated procedure to pre-
vent severe hemolysis by elimination of the majority of incompatible
recipient RBCs as demonstrated by our data. Whether a more inten-
sive immunosuppression can overcome the risk of hemolysis without
affecting the establishment of donor chimerism remains unclear. Nev-
ertheless, close monitoring of patients at risk between days 5 and 15
after SCT is recommended.
205
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Two recently published trials and a meta-analysis reported signiﬁ-
cantly reduced febrile episodes and mortality, respectively, with the
use of FQ prophylaxis in neutropenic cancer patients. Although this
data supports the use of antibiotic prophylaxis (AP), AP does not come
without risks. A concern exists for breakthrough infections withmulti-
drug resistant (MDR) organisms and colonization with resistant bac-
teria. Our institution initiated the use of AP to prevent febrile neu-
tropenia (FN) in high risk cancer patients after the reports above, and
assessed the efﬁcacy of AP in our patients and the incidence of MDR
infection and colonization in neutropenic cancer patients prior to and
after the implementation of AP.
Patients at high risk for FN (hematopoietic stem cell transplant,
leukemia patients undergoing induction or consolidation chemother-
apy, patients with a history of previous FN or undergoing a chemo-
therapy regimen with an expected duration of neutropenia 10 days)
were given AP (moxiﬂoxacin 400 mg daily) initiated the day after
chemotherapy and continued until neutropenia resolved or break-
through fever requiring broad spectrum antibiotics occurred.
Preliminary analysis of 81 patients showed that 38 patients (47%)
developed FN with a mean time to febrile episode of 10.9 days.
Eighteen patients were readmitted for FN, in 19 patients FN oc-
curred during the same hospitalization, and one patient was treated as
an outpatient with IV antibiotics. Seventeen (21%) patients had pos-
itive cultures: blood (6), urine (9), sputum (2). The rate of overall
microbiologically documented infection (21%) is similar, but the rate
of bacteremia (7%) lower than those reported in a similar risk patient
group using levoﬂoxacin AP (18%) (NEJM, 2005;335:977). Evalua-
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